World of DTC Marketing

SEPTEMBER 7, 2022

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Now Biogen is a shell of a company selling off assets to survive. Biogen’s failure should be a warning to other pharma companies. It should be a warning to other pharma companies. ” The U.S.

Pharma Companies 210

Pharma Companies Marketing Drugs Production 210

pharmaphorum

MAY 24, 2021

Robb DeFilippis, managing director, life sciences, for end-to-end global creative production and sourcing partner Tag in the Americas agrees. We’ve even seen cases where assets were not shared among the same brand teams,” Robb explains. Greater emphasis has now been placed on repurposing existing assets, ‘shoot-once-use-many-times’.

Marketing 92

Marketing Branding Sales Life Science 92

XTalks

AUGUST 17, 2020

In 2017, the US FDA approved a CAR-T cell treatment for young adults and children with B-cell ALL. IL-2 is not only a validated T cell target, but is also an approved drug for metastatic melanoma and renal cell carcinoma. The third asset in the pipeline targets a mutated epitope of KRAS, which is a primary tumor driver.

Protein 98

Protein Engineer Immune Response In-Vivo 98

The Pharma Data

MAY 4, 2021

up 28%, primarily driven by continued strong demand in the metastatic and non-metastatic castration-resistant prostate cancer indications, as well as the metastatic castration-sensitive prostate cancer indication, which was approved in the U.S. The FDA action converts the 2018 accelerated approval to full approval.

Vaccination 40

Vaccination Vaccine Production Sales 40